FortuneRock (China) Co., Ltd., a biotechnology and biopharmaceutical company, announced that it has received approval for its initial public offering and listing on the National Equities Exchange and Quotations (NEEQ) or "Xin San Ban" by Chinese regulators on July 30, 2015. The company shares will trade under the new ticker number "NEEQ:833178".
Prof. Zailin YU, Chairman of FortuneRock (China) Co., Ltd. said, "We are happy to announce the successful IPO of our business in China on the NEEQ. This continues our efforts to further expand the company and our extensive novel product pipeline."
About FortuneRock (China) Co., Ltd.
FortuneRock (China) Co., Ltd., a biotechnology and biopharmaceutical company registered in Beijing. Along with its 3 subsidiaries, Tianjin SinoBiotech Ltd., SinoBiotech (Tianjin) Ltd. and Beijing Bio-Fortune Ltd., the group is focused on the discovery, development, and commercialization of novel, patent-protected gene-based recombinant protein drugs with high clinical value for the treatment of life-threatening and debilitating diseases. Currently, the company has one drug with clinical Phase I completed, one in later stage clinical Phase II, another waiting for approval to enter into clinical trials, and several novel drugs in pre-clinical studies, all for different indications.
FortuneRock (China) Co., Ltd. has unique technology platforms with 26 patents filed or granted in USA, China or PCT and all have been published. The Long Acting Recombinant Protein Drug Platform can be used for developing many therapeutic protein drugs for injection with longer half-life or long acting functions on the restructuring of the well known recombinant protein drugs. Along with a High Efficacy Yeast Expression System Platform, FortuneRock can produce kilogram mass quantities of high quality recombinant protein products. FortuneRock has extensive experience in product development and conducting pre-clinical and clinical trials in China for itself and its partners.